MedTrace Logo

Enoxacin for Amyotrophic Lateral Sclerosis (ALS)

NCT04840823 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2024-01-26

No results posted yet for this study

Summary

The study will assess the safety of the drug enoxacin at specific dose levels in adults with ALS.

Conditions

Interventions

DRUG

Enoxacin

Oral 200mg tablet

DRUG

Placebo

Oral tablet

Sponsors & Collaborators

  • Weizmann Institute of Science

    collaborator OTHER

  • Apotex Inc.

    collaborator INDUSTRY

  • McGill University

    lead OTHER

Principal Investigators

  • Angela Genge, MD, FRCP · McGill University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-26
Primary Completion
2023-11-15
Completion
2023-11-15

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04840823 on ClinicalTrials.gov